Overcoming Obstacles to LAI ART Implementation
Weight and metabolic changes after switching from tenofovir alafenamide (TAF)/emtricitabine (FTC)+dolutegravir (DTG), tenofovir disoproxil fumarate (TDF)/FTC+DTG and TDF/FTC/efavirenz (EFV) to TDF/lamivudine (3TC)/DTG.
Bosch B, Akpomiemie G, Chandiwana N, et al. Clin Infect Dis. 2023;76(8):1492-1495.
Long-acting injectable antiretrovirals for HIV treatment in the ICONA cohort: physicians' and nurses' points of view.
Cingolani A, Tavelli A, De Benedittis S, et al; ICONA Foundation Study group. J Antimicrob Chemother. 2024;79(10):2662-2667.
Early experience implementing long-acting injectable cabotegravir/rilpivirine for human immunodeficiency virus-1 treatment at a Ryan White-funded clinic in the US South.
Collins LF, Corbin-Johnson D, Asrat M, et al. Open Forum Infect Dis. 2022;9(9):ofac455.
Patient participant perspectives on implementation of long-acting cabotegravir and rilpivirine: results from the Cabotegravir and Rilpivirine Implementation Study in European Locations (CARISEL) study.
Gutner CA, van der Valk M, Portilla J, et al. J Int Assoc Provid AIDS Care. 2024;23:23259582241269837.
48-week viral suppression rates in people with HIV starting long-acting CAB/RPV with initial viremia.
Hickey MD, Gistand N, Grochowski J, et al. Clin Infect Dis. 2024. [Epub ahead of print]
Safety and effectiveness from the Cabotegravir and Rilpivirine Implementation Study in European Locations study: phase 3b hybrid type III implementation study integrating cabotegravir + rilpivirine long-acting into European clinical settings.
Jonsson-Oldenbüttel C, Ghosn J, van der Valk M, et al. J Acquir Immune Defic Syndr. 2024;96(5):472-480.
Use of injectable CAB/RPV LA as replacement ART in virally suppressed adults.
McGowan J, Fine SM, Vail RM, et al. Johns Hopkins University; 2023.
Expanded multivariable models to assist patient selection for long-acting cabotegravir + rilpivirine treatment: clinical utility of a combination of patient, drug concentration, and viral factors associated with virologic failure.
Orkin C, Schapiro JM, Perno CF, et al. Clin Infect Dis. 2023;77(10):1423-1431.
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.
Overton ET, Richmond G, Rizzardini G, et al. Lancet. 2021;396(10267):1994-2005.
Long-acting injectable CAB/RPV is superior to oral ART in PWH with adherence challenges: ACTG A5359. Rana AI, Bao Y, Zheng L, et al. Conference on Retroviruses and Opportunistic Infections; March 3-6, 2024; Denver, CO. Abstract 212.
Cabotegravir + rilpivirine long-acting: overview of injection guidance, injection site reactions, and best practices for intramuscular injection administration.
Teichner P, Chamay N, Elliot E, et al. Open Forum Infect Dis. 2024;11(6):ofae282.
CLINICAL PRACTICE GUIDELINES
Downloadable Clinician Treatment Guide
Antiretroviral drugs for treatment and prevention of HIV in adults: 2024 recommendations of the International Antiviral Society-USA Panel.
Gandhi RT, Landovitz RJ, Sax PE, et al. JAMA. 2024. [Epub ahead of print]
Updated treatment recommendation on use of cabotegravir and rilpivirine for people with HIV from the IAS-USA Guidelines Panel.
Sax PE, Thompson MA, Saag MS; IAS-USA Treatment Guidelines Panel. JAMA. 2024;331(12):1060-1061.
Consensus recommendations for use of long-acting antiretroviral medications in the treatment and prevention of HIV-1: endorsed by the American Academy of HIV Medicine, American College of Clinical Pharmacy, Canadian HIV and Viral Hepatitis Pharmacists Network, European AIDS Clinical Society, and Society of Infectious Diseases Pharmacists: an executive summary.
Sherman EM, Agwu AL, Ambrosioni J, et al. Pharmacotherapy. 2024;44(7):488-493.
Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV.
US Department of Health and Human Services
CLINICIAN RESOURCES
Clinical Guidelines Program: HIV Treatment
New York State Department of Health AIDS Institute
Clinician-to-Clinician Advice
National Clinician Consultation Center; University of California, San Francisco
Recommendations
US Preventive Services Task Force.
PATIENT AND CAREGIVER RESOURCES
AIDSMap
NAM Publications
Living with HIV
Centers for Disease Control and Prevention
National Institutes of Health
Overcoming Obstacles to LAI ART Implementation
A CME Obstacle Course™ Activity
| Faculty: | Aadia Rana, MD, FIDSA |
| Release: | 02/24/2025 |
| Expiration: | 02/24/2026 |
